AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (45)

Latest Posts

About This Stock More About This Stock
AstraZeneca & Valeant Facing New Competition In The Opioid-Induced Constipation Arena
Article By: Lorimer Wilson
Friday, March 24, 2017 7:48 PM EDT
AstraZeneca & Valeant have been battling it out in the opioid-induced constipation arena with movantik and relistor, respectively, since winning their FDA approvals back in September 2014. Now there’s a third competitor prepping to jump into the mix.
In this article: AZN, VRX, SGIOF
Read
Who Are The Next Acquisition Targets In Dermatology?
Article By: Ari Zoldan
Wednesday, March 22, 2017 8:25 AM EDT
Specialty pharmaceuticals is a highly dynamic sector with robust stock valuations and an active mergers & acquisition market. One of the most attractive areas for investment is dermatology.
In this article: IMNP, AZN, PFE, SNY, ANAC, RGEN, DERM, FOMX, LBTSF
Read
AstraZeneca Reports Positive Phase 2 Results For Cancer Drug
Article By: KKD Healthcare Analytics
Friday, February 17, 2017 12:32 PM EDT
The company stock has gained over 5 percent this year so far. Its 12 months performance is a little shaky as the stock lost 3 percent of its value during this time period.
In this article: AZN
Read
Week In Review: China To Add 300 Drugs To National Reimbursement Drug List
Article By: ChinaBio® Today
Saturday, February 4, 2017 1:21 PM EDT
According to sources, China is getting close to announcing a revised National Reimbursement Drug List, the group of drugs covered by China's national insurance plan. 130 will be chemical drugs and the rest will be traditional Chinese medicines.
In this article: AZN, GSK, FGEN
Read
Cempra Plunges To 52-Week Low, Shire Drug Label Expanded
Article By: Arpita Dutt
Friday, December 30, 2016 10:33 AM EDT
It was a relatively slow week for pharma stocks though a couple of companies suffered regulatory setbacks with the FDA issuing complete response letters (CRLs) for their regulatory applications.
In this article: AMPH, AZN, BMY, CEMP, MRK, MYL, SHPG
Read

PARTNER HEADLINES

Latest Tweets for $AZN

No tweets yet!